ArticleAAPS PharmSciTech2026
Solvent‑Free Bioerodible Ophthalmic Inserts for Mangiferin Delivery: Physicochemical Characterization and In Vivo Evaluation.
Article in AAPS PharmSciTech, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ophthalmic topical dosage forms are often limited by their low bioavailability, primarily due to rapid precorneal clearance. Prolonging the precorneal residence time enables sufficient drug absorption and facilitates the desired pharmacological effects. In this study, mangiferin-loaded ophthalmic inserts were successfully formulated using hydroxypropyl methylcellulose acetate succinate (HPMC AS) as a matrix-forming agent via the hot-melt extrusion technique. The prepared inserts were systematically characterized with respect to morphology, drug-polymer interaction, drug polymorphism, drug content, surface pH, and drug release. A correlation between independent factors and drug release in vitro was established, enabling the customization of drug release profiles. The in vivo study exhibited that the formulation was well tolerant to the rabbit eyes and remained in the lower conjunctival cul-de-sac for over 12 h. Furthermore, the concentration of mangiferin in the lacrimal fluid remained relatively consistent for up to 12 h, thereby allowing sustained exposure of the cornea-conjunctiva surface-the target site of action-to drug therapeutic levels. These findings suggest that the developed ophthalmic inserts offer a promising strategy for the ocular delivery of mangiferin in the treatment of herpes keratitis.
Indexed as
Identifiers
42265524What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.